Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

10.68 -0.41 (-3.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
BMO Initiates Coverage On This Gene Editing Spearhead ↗
 
Via Benzinga
News headline image
Analyst Ratings for Intellia Therapeutics ↗
Over the past 3 months, 7 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Analyst Ratings for Intellia Therapeutics ↗
Over the past 3 months, 8 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Morgan Stanley cut Guardant Health, Inc. (NASDAQ: GH) price target from $120 to $85. Guardant Health shares rose 4.3% to $40.99 in pre-market trading. 
Via Benzinga
News headline image
4 Analysts Have This to Say About Intellia Therapeutics ↗
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter: 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Preview For Intellia Therapeutics ↗
Intellia Therapeutics (NASDAQ:NTLA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call ↗
Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
News headline image
Good Entry Point for Biotech Stocks ↗
Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms. 
Via Talk Markets
News headline image
FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials ↗
The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products. 
Via Benzinga
News headline image
Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today ↗
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis. Buying $100 In NTLA: 5 years ago, an investor could have... 
Via Benzinga
News headline image
Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer ↗
Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has received an FDA orphan drug designation. The autologous T cell receptor therapy, dubbed... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022 ↗
Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics... 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday. DBV Technologies S.A. (... 
Via Benzinga
News headline image
44 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on... 
Via Benzinga
News headline image
80 Biggest Movers From Yesterday ↗
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63... 
Via Benzinga
News headline image
Analyst Ratings For Intellia Therapeutics ↗
Over the past 3 months, 4 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
News headline image
Intellia Shares Updated Data On Gene Editing Durability In Rare Disease ↗
Eight months after delivering promising biomarker data from one of the first CRISPR trials, Intellia Therapeutics Inc (NASDAQ: NTLA) presented additional data... 
Via Benzinga
News headline image
Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗
Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers GBS (NASDAQ:GBS) stock rose 10.9% ... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022 ↗
Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago... 
Via Benzinga
News headline image
How Have Cathie Wood's Top 10 Investments Performed In The Last 6 Months? ↗
Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains. The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020,... 
Via Benzinga
News headline image
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.